The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Oral physostigmine and lecithin improve memory in Alzheimer disease
Abstract
Eight patients with early Alzheimer disease were treated with gradually increasing multiple daily doses of oral physostigmine and supplemental lecithin. Six individuals showed improvement in total recall and retrieva storage (LTR), with a decrease in intrusions (a measure of inaccurate recall). The optimal individual dose was either 2.0 or 2.5 mg of physostigmine for each responding patient. Results of this open trial were subsequently replicated during a double‐blind crossover trial comparing physostigmine treatment to placebo. All six patients again demonstrated improvement in total recall and LTR, with a decrease in intrusions. The decrease in intrusions was strongly correlated with increasing inhibition of cholinesterase activity in cerebrospinal fluid, suggesting that the degree of improvement in the patient's memory was related to the amount of physostigmine that reached the brain. Other improvement and metabolites in cerebrospinal fluid were unaffected by the physostigmine therapy, suggesting a specific effect of physostigmine on the cholinergic system. The results suggest that small oral doses of physostigmin combined with lecithin ingestion have therapeutic benefit for some patients with Alzheimer disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
Methods of Hormone Radioimmunoassay
(1978) · Elsevier eBooks · doi:10.1016/b978-0-123-79260-0.x5001-8 · Cited by 2,077
Evaluating storage, retention, and retrieval in disordered memory and learning
BUSCHKE, H., & FULD, P. A. (1974) · Neurology · doi:10.1212/wnl.24.11.1019 · Cited by 1,597
Self-citationHuman Memory and the Cholinergic System: A Relationship to Aging?
Drachman, D. A. (1974) · Archives of Neurology · doi:10.1001/archneur.1974.00490320001001 · Cited by 1,397
Asher, R. (1961) · The Lancet · doi:10.1016/s0140-6736(61)91217-x · Cited by 1,290
NECROPSY EVIDENCE OF CENTRAL CHOLINERGIC DEFICITS IN SENILE DEMENTIA
Perry, E., Perry, R., Blessed, G., & Tomlinson, B. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91780-9 · Cited by 1,069
Alzheimer's Disease: Senile Dementia and Related Disorders
Bellur, S. N. (1979) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1979.03300200059031 · Cited by 803
Neurotransmitter-related enzymes in senile dementia of the alzheimer type
Davies, P. (1979) · Brain Research · doi:10.1016/0006-8993(79)90336-6 · Cited by 634
NEOCORTICAL CHOLINERGIC NEURONS IN ELDERLY PEOPLE
White, P., Goodhardt, M. J., Keet, J. P., Hiley, C. R., Carrasco, L. H., Williams, I. E. I., & Bowen, D. M. (1977) · The Lancet · doi:10.1016/s0140-6736(77)92114-6 · Cited by 489
A CLICKING HIP IN A NEWBORN BABY SHOULD NEVER BE IGNORED
Cunningham, K. T., Beningfield, S., Moulton, A., & Maddock, C. R. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92180-9 · Cited by 387
Pre- and postsynaptic neurochemical alterations in Alzheimer's disease
Reisine, T. D., Yamamura, H. I., Bird, E. D., Spokes, E., & Enna, S. J. (1978) · Brain Research · doi:10.1016/0006-8993(78)90562-0 · Cited by 342
Davies, P., & Verth, A. H. (1977) · Brain Research · doi:10.1016/0006-8993(77)90758-2 · Cited by 313
Radioimmunoassay for GH-Release Inhibiting Hormone
Arimura, A., Sato, H., Coy, D. H., & Schally, A. V. (1975) · Experimental Biology and Medicine · doi:10.3181/00379727-148-38631 · Cited by 302
Sims, N. R., Smith, C. C. T., Davison, A. N., Bowen, D. M., Flack, R. H. A., Snowden, J. S., & Neary, D. (1980) · The Lancet · doi:10.1016/s0140-6736(80)90884-3 · Cited by 197
Effects of physostigmine and lecithin on memory in Alzheimer disease
Peters, B. H., & Levin, H. S. (1979) · Annals of Neurology · doi:10.1002/ana.410060307 · Cited by 195
Pain Sensitivity in Schizophrenics
(1979) · New England Journal of Medicine · doi:10.1056/nejm197910253011722 · Cited by 158
CLINICAL EFFECTS OF CHOLINE IN ALZHEIMER'S DISEASE
Etienne, P. E., Gauthier, S. G., Johnson, G., Collier, B., Mendis, T., Dastoor, D., Cole, M. G., & Müller, H. (1978) · The Lancet · doi:10.1016/s0140-6736(78)90180-0 · Cited by 105
Richter, J. A., Perry, E. K., & Tomlinson, B. E. (1980) · Life Sciences · doi:10.1016/0024-3205(80)90176-9 · Cited by 105
Enhancement of Memory by Physostigmine
(1979) · New England Journal of Medicine · doi:10.1056/nejm197910253011721 · Cited by 100
Memory Enhancement After Physostigmine Treatment in the Amnesic Syndrome
Peters, B. H., & Levin, H. S. (1977) · Archives of Neurology · doi:10.1001/archneur.1977.00500160029004 · Cited by 98
Diagnostic criteria for primary neuronal degeneration of the Alzheimer's type.
Eisdorfer, C., & Cohén, D. (1980) · PubMed · Cited by 78
Effect of Physostigmine on Constructional and Memory Tasks in Alzheimer's Disease
Muramoto, O., Sugishita, M., SUGITA, H., & TOYOKURA, Y. (1979) · Archives of Neurology · doi:10.1001/archneur.1979.00500440071014 · Cited by 76
Choline chloride fails to improve cognition in Alzheimer's disease
Thal, L. J., Rosen, W. G., Sharpless, N. S., & Crystal, H. (1981) · Neurobiology of Aging · doi:10.1016/0197-4580(81)90022-1 · Cited by 67
Self-citationINFLUENCE OF CHOLINE ON AMNESIA IN EARLY ALZHEIMER'S DISEASE
Signoret, J. L. (1978) · The Lancet · doi:10.1016/s0140-6736(78)92612-0 · Cited by 64
Lecithin and Memory Training in Suspected Alzheimer's Disease
Brinkman, S. D., Smith, R. C., Meyer, J. S., Vroulis, G., Shaw, T., Gordon, J. R., & Allen, R. H. (1982) · Journal of Gerontology · doi:10.1093/geronj/37.1.4 · Cited by 48
Choline in Alzheimer's Disease
Renvoize, E. B., & Jerram, T. (1979) · New England Journal of Medicine · doi:10.1056/nejm197908093010614 · Cited by 33
Choline bitartrate treatment of Alzheimer-type dementias.
Fovall, P., Dysken, M. W., Lazarus, L. W., Davis, J. M., Kahn, R. L., Jope, R. S., Finkel, S. I., & Rattan, P. (1980) · PubMed · Cited by 15
Cited by
Central cholinergic pathways in the rat: An overview based on an alternative nomenclature (Ch1–Ch6)
Mesulam, M.-M., Mufson, E. J., Wainer, B. H., & Levey, A. I. (1983) · Neuroscience · doi:10.1016/0306-4522(83)90108-2 · Cited by 2,328
A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Disease
Davis, K. L., Thal, L. J., Gamzu, E. R., Davis, C. S., Woolson, R. F., Gracon, S. I., Drachman, D. A., Schneider, L. S., Whitehouse, P. J., Hoover, T. M., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210293271801 · Cited by 626
Self-citationCholinesterase inhibitors as Alzheimer's therapeutics (Review)
Sharma, K. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10374 · Cited by 602
Nicotinic acetylcholine binding sites in Alzheimer's disease
Whitehouse, P. J., Martino, A. M., Antuono, P. G., Lowenstein, P. R., Coyle, J. T., Price, D. L., & Kellar, K. J. (1986) · Brain Research · doi:10.1016/0006-8993(86)90819-x · Cited by 486
Transmitter deficits in Alzheimer's disease
Hardy, J., Adolfsson, R., Alafuzoff, I., Bucht, G., Marcusson, J., Nyberg, P., Perdahl, E., Wester, P., & Winblad, B. (1985) · Neurochemistry International · doi:10.1016/0197-0186(85)90050-6 · Cited by 328
Metadata
- Authors
- Thal, L. J., Fuld, P. A., Masur, D. M., & Sharpless, N. S.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 1983-05
- Volume
- 13
- Issue
- 5
- Pages
- 491-496
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1975886348
- Cited by
- 284
- References
- 28
- FWCI
- 22.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.